| ACE2, a promising therapeutic target for pulmonary hypertension. | |
| | |
MedLine Citation:
|
PMID: 21215698 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pulmonary arterial hypertension (PAH) is a chronic lung disease with poor diagnosis and limited therapeutic options. The currently available therapies are ineffective in improving the quality of life and reducing mortality rates. There exists a clear unmet medical need to treat this disease, which necessitates the discovery of novel therapeutic targets/agents for safe and successful therapy. An altered renin-angiotensin system (RAS) has been implicated as a causative factor in the pathogenesis of PAH. Angiotensin II (Ang II), a key effector peptide of the RAS, can exert deleterious effects on the pulmonary vasculature resulting in vasoconstriction, proliferation, and inflammation, all of which contribute to PAH development. Recently, a new member of the RAS, angiotensin converting enzyme 2 (ACE2), was discovered. This enzyme functions as a negative regulator of the angiotensin system by metabolizing Ang II to a putative protective peptide, angiotensin-(1-7). ACE2 is abundantly expressed in the lung tissue and emerging evidence suggests a beneficial role for this enzyme against lung diseases. In this review, we focus on ACE2 in relation to pulmonary hypertension and provide proof of principle for its therapeutic role in PAH. |
| | |
Authors:
|
Vinayak Shenoy; Yanfei Qi; Michael J Katovich; Mohan K Raizada |
Related Documents
:
|
22679538 - Accuracy of cardiac output measurements during off-pump coronary artery bypass grafting... 3654738 - Penetrating trauma of the internal carotid artery at the base of the skull. 22717278 - Surgical repair of atrial septal defect with severe pulmonary hypertension during pregn... 22337258 - Milrinone is preferred to levosimendan for mesenteric perfusion in hypoxia-reoxygenated... 16373248 - Cerebral artery hemodynamics in polycystic ovary syndrome. 19965848 - Aneurysm occlusion in elderly patients with aneurysmal subarachnoid haemorrhage: a cost... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review Date: 2011-01-05 |
Journal Detail:
|
Title: Current opinion in pharmacology Volume: 11 ISSN: 1471-4973 ISO Abbreviation: Curr Opin Pharmacol Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-12 Completed Date: 2011-08-05 Revised Date: 2012-09-20 |
Medline Journal Info:
|
Nlm Unique ID: 100966133 Medline TA: Curr Opin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 150-5 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ltd. All rights reserved. |
Affiliation:
|
Department of Physiology and Functional Genomics, University of Florida, Gainesville, FL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin-Converting Enzyme Inhibitors
/
therapeutic use* Animals Cell Proliferation Endothelium, Vascular / physiology Humans Hypertension, Pulmonary / drug therapy*, etiology Inflammation / prevention & control Muscle, Smooth, Vascular / cytology Oxidative Stress Peptidyl-Dipeptidase A / analysis, physiology* Ventricular Remodeling |
| Grant Support | |
ID/Acronym/Agency:
|
HL 99980/HL/NHLBI NIH HHS; HL102033/HL/NHLBI NIH HHS; R01 HL056921-14/HL/NHLBI NIH HHS; R01 HL056921-16/HL/NHLBI NIH HHS; R01 HL102033-01/HL/NHLBI NIH HHS; R01 HL102033-02/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.17.-/angiotensin converting enzyme 2 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clopidogrel resistance: Case reports of CYP2C19 gene variants in suspected coronary stent thrombosis...
Next Document: Quantitative genetics of Aedes aegypti vector competence for dengue viruses: towards a new paradigm?